{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:56:26Z","timestamp":1781520986080,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01815-5","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:40:19Z","timestamp":1781520019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting"],"prefix":"10.1186","volume":"19","author":[{"given":"Yagya","family":"Ahlawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"5","key":"1815_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/bloodadvances.2020002177","volume":"5","author":"AS Kubasch","year":"2021","unstructured":"Kubasch AS, Fenaux P, Platzbecker U. Development of luspatercept to treat ineffective erythropoiesis. Blood Adv. 2021;5(5):1565\u201375.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"1815_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1182\/blood-2025-792","volume":"146","author":"V Santini","year":"2025","unstructured":"Santini V, Della Porta M, Komrokji R, Pozharskaya V, Farazi T, Keeperman K, Lai Y, Miteva D, Krimmel T, Aggarwal B, Valcarcel D, Fenaux P, Shortt J, Platzbecker U, Garcia-Manero G, Zeidan A. Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial. Blood. 2025;146(Supplement 1):792\u2013792.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1815_CR3","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1182\/blood-2025-4620","volume":"146","author":"I Amanam","year":"2025","unstructured":"Amanam I, Agu C, Korgaonkar S, Hitchens A, Su I-H, Gavrilov S, Tang D, Parikh RC, Davis K, Slaff S. Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US. Blood. 2025;146(Supplement 1):4620\u20134620.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1815_CR4","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1182\/blood-2025-6412","volume":"146","author":"C Willekens","year":"2025","unstructured":"Willekens C, Hnoosh A, Yucel A, Miteva D, Leismann O, Goyal R, Esterberg L, Jimenez M, Germing U. Treatment patterns and clinical outcomes in patients with lower-risk Myelodysplastic Syndromes rreated with first-line luspatercept: Findings from a medical record review in France and Germany. Blood. 2025;146(Supplement 1):6412\u20136412.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1815_CR5","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1182\/blood-2025-5638","volume":"146","author":"M Sekeres","year":"2025","unstructured":"Sekeres M, Hnoosh A, Yucel A, Miteva D, Krimmel T, Slaff S, Tang D, Che M, Wang Y. Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States. Blood. 2025;146(Supplement 1):5638\u20135638.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1815_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood-2025-789","volume":"146","author":"A Zeidan","year":"2025","unstructured":"Zeidan A, Diez-Campelo M, Santini V, Buckstein R, Ad\u00e8s L, Sahagun L, Das G, Zelinsky T, Lai Y, Miteva D, McBride A, Nadal JA, Madry K, Valcarcel D, Torregrosa Diaz JM, Deeren D, Grosicki S, Venugopal S, Platzbecker U, Della Porta M. Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus. Blood. 2025;146(Supplement 1):789\u2013789.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1815_CR7","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1182\/blood-2025-5631","volume":"146","author":"EN Oliva","year":"2025","unstructured":"Oliva EN, Riva M, Frairia C, Crisa E, Poloni A, Alati C, Delfino I, Capodanno I, Pane F, Castelli A, Gurnari C, Voso MT, Zini G, D\u2019Errigo MG, Mamm\u00ec C, Ianni\u2019 G, Marchetti M, Barill\u00e0 S, Bova I, Cannat\u00e0 MC, Rizzo L, Fattizzo B. Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory\/resistant\/intolerant to prior treatments (QOL-ONE Phoenix). Blood. 2025;146(Supplement 1):5631\u20135631.","journal-title":"Blood"},{"issue":"10423","key":"1815_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","volume":"403","author":"U Platzbecker","year":"2024","unstructured":"Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, D\u00edez-Campelo M, Valc\u00e1rcel D, Illmer T, Jon\u00e1\u0161ov\u00e1 A, B\u011blohl\u00e1vkov\u00e1 P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10423):249\u201360.","journal-title":"Lancet"},{"issue":"1","key":"1815_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-025-01775-2","volume":"19","author":"E Cousin","year":"2026","unstructured":"Cousin E, Picard A, Oundjian M, Tardif N, Quemener A, Rio A-G, Galibert M-D, Gandemer V, Mazurier F. Molecularly targeted therapy and immunotherapy in leukemias. J Hematol Oncol. 2026;19(1):12.","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"1815_CR10","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood-2025-2074","volume":"146","author":"V Santini","year":"2025","unstructured":"Santini V, Komrokji R, Savona M, Diez-Campelo M, Fenaux P, Sekeres M, Madanat Y, Valcarcel D, Jonasova A, Belohlavkova P, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Feller F, Navada S, Zeidan A, Platzbecker U. Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS). Blood. 2025;146(Supplement 1):2074\u20132074.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1815_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood-2025-490","volume":"146","author":"A Zeidan","year":"2025","unstructured":"Zeidan A, Santini V, Diez-Campelo M, Savona M, Sekeres M, Madanat Y, Fenaux P, Raza A, Mittelman M, Th\u00e9pot S, Buckstein R, Germing U, Valcarcel D, Jonasova A, Shah S, Xia Q, Sun L, Navada S, Berry T, Platzbecker U, Komrokji R. Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial. Blood. 2025;146(Supplement 1):490\u2013490.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1815_CR12","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1182\/blood-2025-5155","volume":"146","author":"L Ades","year":"2025","unstructured":"Ades L, Lane S, Garnier A, Cluzeau T, Rauzy O, G\u00f6tze KS, Giagounidis A, Singhal D, Brauer D, Grove C, Mohr K, Chermat F, Nkyekyer J, Platzbecker U. A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy \u2013 interim analysis results of the IMpress study. Blood. 2025;146(Supplement 1):5155\u20135155.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01815-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:40:22Z","timestamp":1781520022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01815-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1815"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01815-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}